Phaseline

Targets › SLC19A3

SLC19A3 (Thiamine transporter 2): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 2 Phase 2, 1 Phase 4; Neurology, Ophthalmology, Psychiatry; next expected readout Jun 2027.

Mediates high affinity thiamine uptake, probably via a proton anti-port mechanism. Has no folate transport activity. (UniProt, Q9BZV2)

Open in Phaseline: the race on SLC19A3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Thammasat UniversityBenfotiamine
Lipophilic thiamine derivative (fat-soluble form of vitamin B1)
SLC19A3Phase 4Diabetic Peripheral Neuropathy (DPN)Jun 2027
Columbia UniversityNicotinamide and Pyruvate
NAD+ precursor and mitochondrial energy substrate
SLC19A3Phase 2Primary Open Angle GlaucomaAug 2027
Institut National de la Santé Et de la Recherche Médicale, FranceThiamine
Thiamine supplementation to reduce brain injury and cognitive impairment associated with c
SLC19A2, SLC19A3Phase 2Alcohol Use DisorderOct 2027

Conditions

Diabetic Peripheral Neuropathy (DPN) (1) Primary Open Angle Glaucoma (1) Alcohol Use Disorder (1)

Modalities

small molecule (3)

Companies

Thammasat University (1) Columbia University (1) Institut National de la Santé Et de la Recherche Médicale, France (1)

Related targets

SLC19A2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.